8-K: Vicarious Surgical: ATM Offering, Warrants Delisted, Cash Burn Cut

Vicarious Surgical announced an At-The-Market offering, the delisting of its warrants from the NYSE, and a reduced cash burn guidance for 2026.

Summary

• Vicarious Surgical Inc. entered into an At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC on December 12, 2025, to sell Class A common stock from time to time.
• The aggregate market value of shares eligible for sale under the ATM offering is currently $2,286,052, subject to the effectiveness of a shelf registration statement on Form S-3.
• The Sales Agent will receive a commission of 3.0% of the gross proceeds from stock sales and will be reimbursed for certain expenses, including up to $50,000 for initial counsel fees and up to $3,500 per due diligence update session.
• On December 15, 2025, the NYSE notified the company of its decision to delist and immediately suspend trading in the company's Public Warrants (RBOT.WS) due to abnormally low trading price levels.
• The company does not intend to appeal the NYSE's delisting determination for the warrants.
• Trading in the company's Class A common stock (RBOT) will continue on the NYSE, but remains subject to regaining compliance with Section 802.01B of the NYSE's Listed Company Manual by October 10, 2026.
• The company announced full-year 2026 cash burn guidance of approximately $35 million, representing a $10 million improvement from its updated 2025 guidance of $45 million.
• Key drivers for the improved cash burn guidance include reductions in headcount and external consulting spend, partially offset by increased strategic outsourcing.
• Cash needs beyond existing resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million, with design freeze targeted by year-end 2026.

Sentiment

Score: 3

Explanation: The delisting of warrants due to abnormally low trading prices is a significant negative event, reflecting poor market performance for a segment of the company's securities. While the improved cash burn guidance is positive, the overall sentiment is dampened by the delisting and the ongoing need to address common stock listing compliance, indicating substantial challenges.

Positives

• The company expects a full-year 2026 cash burn of approximately $35 million, which is a $10 million improvement from the recently updated 2025 guidance of $45 million.
• The improved cash burn guidance reflects a strong continuation of the company's operational reset, driven by reductions in headcount and external consulting spend.
• The company is selectively leveraging outsourcing to remain on track toward achieving design freeze by year-end 2026.

Negatives

• The NYSE has determined to delist the company's Public Warrants (RBOT.WS) and immediately suspend trading due to abnormally low trading price levels.
• The company does not intend to appeal the NYSE's determination regarding the warrant delisting.
• The company's common stock (RBOT) remains subject to regaining compliance with NYSE listing standards (Section 802.01B) by October 10, 2026.

Risks

• No assurances are made as to if or whether the shelf registration statement on Form S-3 will become effective or, if effective, as to its continued effectiveness.
• There is no assurance that the Sales Agent will be successful in selling shares under the ATM Agreement.
• The company's ability to maintain the listing of its Class A common stock on the New York Stock Exchange is contingent on regaining compliance with Section 802.01B by October 10, 2026.
• Risks related to the approval, commercialization, and adoption of the company's product candidates and the success of its surgical robot.
• Changes in applicable laws or regulations could adversely affect the business.
• The company's ability to raise future financing is uncertain.
• Risks associated with the cost and timing of product and service development activities.
• The company's ability to obtain and maintain regulatory approval for its surgical system and any related restrictions.
• The size and duration of human clinical trials for the surgical system.
• The company's ability to identify, in-license, or acquire additional technology.
• The company's ability to maintain existing license, manufacture, supply, and distribution agreements.
• Competition from other companies marketing or developing similar products and services.
• Uncertainty regarding the size and growth potential of target markets and the company's ability to serve them.
• Risks related to the pricing of products and services and reimbursement for medical procedures.
• Economic downturns, political, and market conditions could adversely affect the business, financial condition, and results of operations.
• Challenges in protecting or enforcing intellectual property rights and the potential impact of failure to do so.

Future Outlook

The company aims to achieve design freeze on its Vicarious Surgical system by year-end 2026. It plans to continue its cost management strategy, including headcount reductions and leveraging strategic outsourcing, to improve its cash burn profile, targeting approximately $35 million for fiscal year 2026.

Management Comments

• "Our cost management strategy continues to demonstrate improved discipline as we operate as a leaner organization," said Stephen From, Chief Executive Officer.
• "We have made deliberate decisions to reduce internal costs while selectively leveraging outsourcing to remain on track toward achieving design freeze by year-end 2026."

Industry Context

Vicarious Surgical operates in the highly competitive and capital-intensive next-generation robotics technology sector, specifically focused on transforming robotic surgery. The company's strategic shift towards cost management, headcount reduction, and increased outsourcing, alongside a capital raise attempt via an ATM offering, suggests a focus on conserving resources and streamlining operations to reach critical development milestones (like design freeze) in a challenging funding environment or as part of a broader industry trend towards efficiency.

Stakeholder Impact

• Shareholders of the Public Warrants (RBOT.WS) will experience immediate suspension of trading and delisting, resulting in a loss of liquidity and potentially value for their holdings.
• Common stock shareholders (RBOT) face continued uncertainty regarding the company's ability to maintain its NYSE listing, which could impact stock liquidity and investor confidence.
• The At-The-Market offering introduces potential dilution for existing common stock shareholders.
• Employees are impacted by headcount reductions, which are a key driver for the improved cash burn guidance.

Next Steps

• Proceed with the At-The-Market (ATM) offering for Class A common stock, subject to the effectiveness of the Form S-3 registration statement.
• Work towards regaining compliance with NYSE listing standard Section 802.01B for its common stock by the October 10, 2026 deadline.
• Continue operational reset and cost management strategies to achieve the targeted $35 million cash burn for fiscal year 2026.
• Advance development of the Vicarious Surgical system to achieve design freeze by year-end 2026.

Key Dates

Recommendation

The delisting of the company's warrants from the NYSE due to "abnormally low trading price levels" is a severe negative indicator of market confidence and the company's financial health. Although cash burn guidance improved, the initiation of an At-The-Market offering suggests a need for capital, and the common stock remains under a compliance review for continued listing. These factors collectively point to significant headwinds and warrant a cautious, if not outright negative, stance on the stock.

Keywords

Robotic surgery, ATM offering, NYSE delisting, Cash burn guidance, Financial reporting, SEC filing, RBOT, Warrants, Capital raise, Medical technology